Newsroom

LATEST PUBLICATIONS

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas

2021-02-13T00:42:37-08:00August 15th, 2014|

Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma

2021-02-13T00:46:19-08:00August 13th, 2014|

The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies

2021-02-12T20:42:59-08:00April 5th, 2014|

Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients

2021-02-18T21:08:35-08:00November 15th, 2013|

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

2021-02-18T21:10:55-08:00October 31st, 2013|

CONFERENCES

No conferences from the last year found.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Newsroom

Newsroom

LATEST PUBLICATIONS

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas

Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma

The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies

Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

LATEST PRESS

CONFERENCES

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Newsroom

Newsroom

LATEST PUBLICATIONS

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas

Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma

The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies

Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

LATEST PRESS

CONFERENCES

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.